Table 2.
Clinical, surveillance and treatment characteristics of AA and CA men in PASS.
| Variable | AA only (n=89) | CA only (n=1226) |
|---|---|---|
| n (%) or median [IQR] | n (%) or median [IQR] | |
| Length of Follow-up, years1 | 2.9 [2.0, 4.6] | 3.9 [2.2, 6.0] |
| Number surveillance biopsies | 2 [1, 2] | 2 [1,3] |
| Number PSA/year | 3 [2, 4] | 3 [3, 4] |
| mpMRI use | 23 (26) | 365 (30) |
| Grade reclassification | 30 (34) | 419 (34) |
| Treatment (any) | 30 (34) | 411 (34) |
| RP | 13 (43) | 233 (57) |
| RAD | 17 (57) | 155 (38) |
| ADT/Other | 0 | 23 (5) |
| Adverse Pathology at RP* | 6/13 (46) | 109/233 (47) |
1
Among men who did not reclassify